# A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

> **NCT02124850** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 18 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Motolimod
- **DRUG:** Cetuximab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02124850
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-28
- **Primary completion:** 2016-08-11
- **Final completion:** 2016-10-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124850, "A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02124850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*